Vol 55, No 4 (2024)
Clinical vignette
Published online: 2024-08-29
Effective treatment of autoimmune thrombocytopenia with rituximab in CLL patient undergoing therapy with acalabrutinib
12
, 12
, 12
DOI: 10.5603/ahp.101337
Acta Haematol Pol 2024;55(4):224-225.
Abstract
N/A
Keywords: chronic lymphocytic leukemiaimmune thrombocytopeniaacalabrutinibsteroid-resistantrituximab
References
- Eichhorst B, Robak T, Montserrat E, et al. Chronic lymphocytic leukaemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2021; 32(1): 23–33.
- Fattizzo B, Barcellini W. Autoimmune cytopenias in chronic lymphocytic leukemia: focus on molecular aspects. Front Oncol. 2020; 10(9): 1435.
- Hus I, Giannopoulos K, Jamroziak K, et al. Diagnostic and therapeutic recommendations of the Polish Society of Haematologists and Transfusiologists, and Polish Adult Leukemia Group-CLL for chronic lymphocytic leukemia in 2023. Acta Haematol Pol. 2023; 54(6): 342–371.
- Hampel PJ, Larson MC, Kabat B, et al. Autoimmune cytopenias in patients with chronic lymphocytic leukaemia treated with ibrutinib in routine clinical practice at an academic medical centre. Br J Haematol. 2018; 183(3): 421–427.
- Robak E, Robak T. Bruton's kinase inhibitors for the treatment of immunological diseases: current status and perspectives. J Clin Med. 2022; 11(10): 2807.
- Puła B, Iskierka-Jażdżewska E, Jamroziak K, et al. Expert opinion on use of acalabrutinib for chronic lymphocytic leukemia treatment. Acta Haematol Pol. 2024; 55(3): 130–136.
- Tryc-Szponder J, Joks M, Gil L. Autoimmune cytopenias in chronic lymphocytic leukemia: a growing challenge in targeted therapies? Acta Haematol Pol. 2022; 53(5): 316–325.
- Oyama T, Yasunaga M, Jona M, et al. Acalabrutinib and steroid for autoimmune thrombocytopenia due to relapsed chronic lymphocytic leukemia with severe bone marrow infiltration. J Clin Exp Hematop. 2023; 63(3): 187–192.
- D'Arena G, Capalbo S, Laurenti L, et al. Chronic lymphocytic leukemia-associated immune thrombocytopenia treated with rituximab: a retrospective study of 21 patients. Eur J Haematol. 2010; 85(6): 502–507.
- Nikitin E, Kislova M, Morozov D, et al. Ibrutinib in combination with rituximab is highly effective in treatment of chronic lymphocytic leukemia patients with steroid refractory and relapsed autoimmune cytopenias. Leukemia. 2023; 37(7): 1464–1473.